GHRH Analogues & GH Secretagogues
GHRH analogue and GH secretagogue research peptides: sermorelin, tesamorelin, CJC-1295 (with and without DAC), ipamorelin, 99%+ HPLC, COA per lot. Research use only.
CJC-1295 DAC
GHRH analog with a drug-affinity complex extending its...
CJC / IPA Blend
A GHRH analog and a GH secretagogue in one vial. 99%+ HPLC,...
TESA / IPA Blend
Tesamorelin and ipamorelin in a single vial. 99%+ HPLC,...
Tesamorelin 10-Pack
Tesamorelin, ten 10mg vials in a protective case.
About GHRH Analogues & GH Secretagogues
This class groups peptides by the receptor they are studied against. Sermorelin, tesamorelin and both CJC-1295 forms are analogues of the first 29 or 44 residues of growth hormone-releasing hormone and are studied at the GHRH receptor. Ipamorelin is a pentapeptide studied at the ghrelin receptor GHSR-1a. The CJC/IPA and Tesa/IPA blends each pair one of each in a single vial.
The compounds differ structurally in chain length and modification. Sermorelin is GHRH(1-29) with an amidated C-terminus. Tesamorelin is GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus. CJC-1295 without DAC is a modified GRF(1-29) with four amino acid substitutions that resist protease cleavage; the DAC form adds a maleimidopropionic acid group at lysine 8 that binds serum albumin in vitro. Ipamorelin is five residues.
Certificates for this class report HPLC purity and identity per lot in the same way as every other compound on the site. Sequence length matters for identity testing: the 44-residue tesamorelin and the 29- and 30-residue GHRH analogues are confirmed by mass against their expected values, and the five-residue ipamorelin by mass and retention.
Regulatory note: peptides in this class appear on the World Anti-Doping Agency prohibited list under peptide hormones and growth factors, and an approved pharmaceutical formulation of tesamorelin exists for one indication. The research-grade material sold here is for in vitro research only and is not that product. Each product page carries its own status line and its monograph in the research library.